Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Peter A MerkelJohn NilesRichard JimenezRobert F SpieraBrad H RovinAndrew BombackChristian PagnouxAntonia PotarcaThomas J SchallPirow Bekkernull null

Published in: ACR open rheumatology (2020)

Avacopan in addition to SOC for ANCA-associated vasculitis was well tolerated, and at the higher study dose, it appeared to improve time to remission (ClinicalTrials.gov identifier NCT02222155).

Keyphrases

binding protein